2025 marks our 15th year, and one of our greatest joys has been witnessing companies grow from inception to this! Please join us in congratulating Oculis and Riad SHERIF - a respected member of the innovation community - on a banner start to 2025! We look forward to keeping up with the next 10 months, Team Oculis!
Very pleased to share the news of a $100 million oversubscribed offering to fuel the growth of Oculis’ portfolio, particularly the progress of Privosegtor (OCS-05), a groundbreaking neuroprotective candidate. In early January, we unveiled the promising top-line outcomes from the Phase 2 ACUITY trial, demonstrating Privosegtor’s neuroprotective impact on both anatomical and visual functions in patients with acute optic neuritis. The results also underscored its potential broad application across various neuro-ophthalmic and neurological conditions like glaucoma, neurotrophic keratitis, and multiple sclerosis. A heartfelt thank you to all our existing and new investors for their incredible backing. This funding round will catapult Oculis to new horizons, empowering us to push our pipeline forward and accelerate the advancement of Privosegtor (OCS-05) For more information, read the full press release:?https://bit.ly/40ZYTEV ? #Oculis #ClinicalTrial #Biotech #DrugDevelopment #Ophthalmology #Biopharma #RethinkingOphthalmology #financing #Nasdaq #OCS-05 #Privosegtor #Neuroprotection
Thank you so much OIS, truly privileged to be part of this group.
Congratulations to the Oculis team! Looking forward to future updates on OCS-05 clinical development.